Insys Therapeutics, Inc. to Present at June Conferences
May 31 2017 - 6:50AM
Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY)
today announced that Saeed Motahari, President and Chief Executive
Officer, and Darryl Baker, Chief Financial Officer, will present at
the following healthcare conferences in June:
Conference: |
|
|
|
Jefferies 2017 Global
Healthcare Conference |
Date: |
|
|
|
Thursday, June 8,
2017 |
Time: |
|
|
|
11:00 a.m. Eastern
Daylight Time |
Location: |
|
|
|
Grand Hyatt New
York |
Webcast: |
|
|
|
http://wsw.com/webcast/jeff105/insy |
|
|
|
|
|
Conference: |
|
|
|
The JMP Securities Life
Sciences Conference |
Date: |
|
|
|
Wednesday, June 21,
2017 |
Time: |
|
|
|
12:30 p.m. Eastern
Daylight Time |
Panel Discussion: |
|
|
|
Opioids |
Location: |
|
|
|
The St. Regis New York
|
Webcast: |
|
|
|
Please note that JMP
Securities will not webcast panel discussions. |
The Jefferies presentation will be webcast live at the
aforementioned time as well as archived for 90 days thereafter, via
the Company’s website at www.insysrx.com, under the Investors
Section.
About INSYS Insys Therapeutics is a specialty
pharmaceutical company that develops and commercializes innovative
drugs and novel drug delivery systems of therapeutic molecules that
improve the quality of life of patients. Using proprietary
sublingual spray technology and capabilities to develop
pharmaceutical cannabinoids, INSYS is developing a pipeline of
products intending to address unmet medical needs and the clinical
shortcomings of existing commercial products. INSYS currently
markets one product, SUBSYS® (fentanyl sublingual spray), CII, and
has received approval for the marketing of SYNDROS™ (dronabinol)
oral solution, CII, a proprietary, orally administered liquid
formulation of dronabinol that INSYS believes has distinct
advantages over the current formulation of dronabinol in soft gel
capsule. INSYS is committed to developing medications for
potentially treating addiction to opioids, opioid overdose,
epilepsy, and other disease areas with a significant unmet
need.
SUBSYS® and SYNDROS™ are trademarks of Insys Development
Company, Inc., a subsidiary of Insys Therapeutics, Inc.
Contact:
Lisa M. Wilson
T: 212-452-2793
E: INSYS@insysrx.com
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From Apr 2024 to May 2024
INSYS THERAPEUTICS, INC. (NASDAQ:INSY)
Historical Stock Chart
From May 2023 to May 2024